콘텐츠로 건너뛰기
Merck
  • In vivo studies on the oridonin-loaded nanostructured lipid carriers.

In vivo studies on the oridonin-loaded nanostructured lipid carriers.

Drug delivery (2012-08-30)
Dandan Zheng, Wenting Dai, Dianrui Zhang, Cunxian Duan, Lejiao Jia, Yue Liu, Qiang Zhang
초록

Oridonin (ORI)-loaded Nanostructured lipid carriers (NLC) were prepared by emulsion-evaporation and low temperature-solidification technique, and evaluated for morphological observation, particle size, zeta potential and in vitro drug release. Next, the characteristics of biodistribution and pharmacokinetics in vivo were examined. The average particle size of resultant NLC was 245.2 nm and the zeta potential was found to be -38.77 mV. The in vivo characteristics of ORI-loaded NLC were studied after intravenous administration using Kunming strain mice as experimental animals. An ORI control solution was studied parallelly. In tested organs, the distribution of ORI-loaded NLC to liver was higher than that of free drug. ORI-loaded NLC showed higher AUC (area under tissue concentration-time curve) values and circulated in the blood stream for a longer time compared with ORI solution. These results support the potential applications of NLC for the delivery of ORI.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Oridonin, ≥98% (HPLC), solid